FIELD: medicine.
SUBSTANCE: invention relates to a calcitocine peptide mimetic represented by: AcCSNLSTCVLGKLSQELHKLQTYPRTDVGANAP-NH2 SEQ ID NO: 15. The peptide is arranged with a carrier for oral administration, and the carrier enhances the oral bioavailability of the peptide. This peptide is used for the treatment of type I diabetes, type II diabetes, metabolic syndrome or obesity, or for appetite suppression, or for insulin resistance decrease, or for reduction of undesirably high levels of fasting serum glucose, or for reduction of undesirable high maximum level of serum glucose, or reduction of undesirably high maximum level of serum insulin, or for attenuation of undesirable strong reaction to the glucose tolerance test.
EFFECT: higher efficacy of compound application.
6 cl, 19 dwg, 15 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| TREATING DIABETES AND METABOLIC SYNDROME | 2010 |
|
RU2537181C2 |
| MIMETIC CALCITONIN FOR TREATING DISEASES AND DISORDERS | 2014 |
|
RU2689551C1 |
| PEPTIDE HAVING AMYLIN PROPERTIES (VERSIONS) AND USE THEREOF (VERSIONS) | 2005 |
|
RU2385878C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATING METABOLIC SYNDROME | 2011 |
|
RU2732703C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATING METABOLIC SYNDROME | 2011 |
|
RU2593960C2 |
| METHODS FOR MODULATING INTESTINAL MICROBIOTA | 2017 |
|
RU2738265C2 |
| TREATMENT OF LIVER, BILE DUCT AND PANCREATIC DISORDERS | 2017 |
|
RU2740913C2 |
| ANALOGUES OF LONG-ACTING PEPTIDES | 2012 |
|
RU2664859C2 |
| ORAL ADMINISTRATION OF PARATHYROID HORMONE AND CALCITONIN | 2002 |
|
RU2300392C2 |
| FUSED DRUG CONSTRUCTS AND CONJUGATES | 2005 |
|
RU2428431C2 |
